Related Experiment Videos
Rotigotine Transdermal Patch: A Review in Parkinson's Disease
1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. demail@springer.com.
CNS Drugs
|June 28, 2019
Summary
Rotigotine transdermal patch (TP) offers a once-daily treatment for Parkinson's disease (PD), improving motor function and quality of life. It is well-tolerated and suitable for patients preferring non-oral administration.
Area of Science:
- Neurology
- Pharmacology
- Dermatology
Background:
- Rotigotine is a non-ergolinic dopamine agonist delivered via a 24-hour transdermal patch (TP).
- It is approved in the EU and globally for early and advanced Parkinson's disease (PD), as monotherapy or adjunct to levodopa.
Purpose of the Study:
- To review the efficacy, safety, and tolerability of the rotigotine TP for Parkinson's disease treatment.
- To assess its impact on motor and non-motor symptoms, including quality of life.
Main Methods:
- Systematic review of clinical trials and meta-analyses involving rotigotine TP.
- Inclusion of studies comparing rotigotine TP with oral dopamine agonists and placebo.
Main Results:
- Rotigotine TP demonstrated efficacy in improving motor and overall functioning in early and advanced PD.
- Improvements were observed in non-motor symptoms, particularly sleep disturbances and health-related quality of life (HRQOL).
- The adverse event profile was consistent with dopaminergic stimulation and patch application; generally well-tolerated.
Conclusions:
- Rotigotine TP is a well-established, once-daily formulation for short- and long-term PD management.
- It provides a convenient alternative to oral medications, especially for patients with gastrointestinal issues.